New drug could help boys with duchenne walk and move longer
NCT ID NCT07608432
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called DYNE-251 in boys aged 4 to 18 with Duchenne muscular dystrophy (DMD) who can still walk. The goal is to see if it helps them move better and slows muscle damage. Participants will receive either the drug or a placebo every 4 weeks for about a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL, HEREDITARY, AND NEONATAL DISEASES AND ABNORMALITIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rare Disease Research, LLC
RECRUITINGHillsborough, North Carolina, 27278, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug help boys with duchenne muscular dystrophy build muscle protein?
- Can a robotic suit help kids with neurological conditions walk better?
- Can tracking muscle changes unlock better duchenne treatments?
- Can a targeted infusion slow muscle decline in duchenne? a new trial aims to find out.
- New drugs aim to slow muscle decline in duchenne muscular dystrophy
- AI-Powered heart scans aim to predict deadly complications in muscular dystrophy